XOMA (NASDAQ:XOMA) Downgraded by StockNews.com to “Sell”

XOMA (NASDAQ:XOMA) was downgraded by equities research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Tuesday.

Separately, HC Wainwright dropped their price target on shares of XOMA from $123.00 to $104.00 and set a “buy” rating for the company in a research note on Monday, February 3rd.

XOMA Price Performance

Shares of XOMA stock traded down $0.43 on Tuesday, hitting $23.10. 25,808 shares of the stock traded hands, compared to its average volume of 47,531. The firm has a market cap of $272.19 million, a price-to-earnings ratio of -6.64 and a beta of 0.90. The firm has a 50 day simple moving average of $26.13 and a two-hundred day simple moving average of $28.00. XOMA has a 52 week low of $21.27 and a 52 week high of $35.00. The company has a debt-to-equity ratio of 1.28, a current ratio of 7.52 and a quick ratio of 7.52.

Insider Buying and Selling at XOMA

In other news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the stock in a transaction on Friday, January 24th. The shares were sold at an average price of $26.10, for a total value of $13,069,366.20. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 7.20% of the stock is currently owned by company insiders.

Institutional Trading of XOMA

Hedge funds and other institutional investors have recently made changes to their positions in the business. BNP Paribas Financial Markets lifted its holdings in XOMA by 95.0% during the third quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 795 shares in the last quarter. State Street Corp lifted its holdings in XOMA by 1.2% during the third quarter. State Street Corp now owns 142,857 shares of the biotechnology company’s stock valued at $3,783,000 after purchasing an additional 1,754 shares in the last quarter. Barclays PLC lifted its holdings in XOMA by 300.7% during the third quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock valued at $298,000 after purchasing an additional 8,447 shares in the last quarter. Geode Capital Management LLC lifted its holdings in XOMA by 0.6% during the third quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company’s stock valued at $4,840,000 after purchasing an additional 1,138 shares in the last quarter. Finally, Rhumbline Advisers lifted its holdings in XOMA by 18.1% during the fourth quarter. Rhumbline Advisers now owns 11,065 shares of the biotechnology company’s stock valued at $291,000 after purchasing an additional 1,699 shares in the last quarter. Institutional investors and hedge funds own 95.92% of the company’s stock.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.